摘要
目的:探讨减低剂量地西他滨治疗骨髓增生异常综合征伴单系发育不良(MDS-SLD)患者的临床疗效和安全性。方法:使用减低剂量地西他滨[15 mg/(m^2·d),连续5 d]治疗12例MDS-SLD患者,观察其疗效和不良反应。结果:2例(16.6%)获完全缓解,1例(8.3%)获部分缓解,5例(41.6%)达血液学改善,总反应率达66.6%。在5例可行细胞遗传学评估的患者中,1例(20.0%)获PR。Ⅳ级血液学毒性发生率50.0%,Ⅲ~Ⅳ级感染发生率33.3%,无Ⅲ~Ⅳ级出血,无Ⅲ~Ⅳ级恶心呕吐和Ⅲ~Ⅳ级肝功能损伤。中位随访时间16(2~32)个月,随访期间无患者死亡。结论:减低剂量地西他滨治疗骨髓增生异常综合征完全缓解及部分缓解率高,药物不良反应发生率低。
Objective:To observe the clinical effect of dose-reduced decitabine in the treatment of patients with myelodysplastic syndrome with single lineage dysplasia(MDS-SLD).Methods:Clinical data of 12 cases of MDS-SLD were collected,and all patients were treated by dose-reduced decitabine(15 mg/m^2 intravenously once daily for 5 days).The efficacy and side-effects of therapy in these patients were evaluated.Results:Of all 12 patients,2 cases(16.6%)achieved complete remission(CR),1 case achieved partial remission(8.3%),5 cases(41.6%)achieved hematologic improvement(HI),and the overall response rate(ORR)was 66.6%.Of the 5 cases in whom cytogenetic evaluation could be performed,1 case(20.0%)achieved partial cytogenetic remission.GradeⅣhematologic toxicity rate was 50.0%,and gradeⅢ-Ⅳinfection rate was 33.3%.No gradeⅢ-Ⅳbleeding,severe nausea and vomiting(gradeⅢ-Ⅳ)and liver injury(Ⅲ-Ⅳ)occurred.The median follow-up time was 16 months(2-32 months).At the end of follow-up,no patients were dead.Conclusion:In the treatment of MDS,the rate of CR and PR was high,and the incidence of adverse drug reactions was low.
作者
龚辉
陈姣
杜芳
周凌云
刘丹波
康春香
GONG Hui;CHEN Jiao;DU Fang;ZHOU Ling-yun;LIU Dan-bo;KANG Chun-xiang(Shenzhen Luohu District Peoples Hospital,Shenzhen 518001,China)
出处
《内科急危重症杂志》
2019年第2期107-109,共3页
Journal of Critical Care In Internal Medicine
基金
深科技创新2017(No:131)